1800 244 735

Helpline (02) 9874 9777

Stem-cell neurons make the right connections

New work suggests that neurons made from stem cells can replace adult neurons better than we thought – at least in mice whose brains have been injured with a toxin. How likely is this to help HD patients – is cell replacement possible in a more chronic condition?

HD and the loss of brain cells

Huntington’s disease is caused by neurodegeneration, or loss of brain cells called neurons. Early in HD, this cell loss particularly affects neurons in a part of the brain called the striatum. Even within the striatum, one type of neuron called a ‘medium spiny neuron’ is most susceptible to degeneration. These neurons make up 96% of the striatum, so losing them is bad news for this part of the brain.

The symptoms of Huntington’s disease reflect this distinctive pattern of cell loss. The striatum helps to control our body’s movement and emotions, as well as performing cognitive tasks, such as learning, multi-tasking and problem solving. These are all areas reported by patients to be affected by Huntington’s disease.

The problem with neurodegenerative diseases like HD is that once vulnerable neurons like the medium spiny neurons are lost, they do not grow back. As far as we understand now, once they’re gone, they’re gone.

The brain can cope with loss

The TRACK-HD project, led by Professor Sarah Tabrizi, used MRI scans to reveal a noticeable loss of brain tissue early in the course of the disease. This progression of neuron loss is seen even before symptoms are reported by the patients.

In one way, this is bad news – the brains of HD mutation carriers are shrinking even before they experience symptoms that we call ‘HD’. But another way of looking at this is very hopeful – despite the fact that most neurons cannot regenerate, the brain can still show remarkable flexibility to compensate and maintain normal function.

Since degeneration of the medium spiny neurons in the striatum causes the symptoms of Huntington’s disease, one approach to treatment would be to replace the neurons that have been lost.

Cell replacement in brain diseases

While this may sound a little like science fiction, it might be more feasible than once thought. For treatment of Parkinson’s disease, this approach has already been undertaken with moderate success.

Parkinson’s disease is caused by degeneration of a tiny but important set of neurons that produce a brain chemical called ‘dopamine’. Loss of these cells causes tremors, stiffness and poor coordination.

In clinical trials, cells from fetal tissue have been transplanted into the brains of patients with Parkinson’s Disease, resulting – in some cases – in marked improvements in their movement abnormalities and overall health.

However, compared to Huntington’s Disease, treating Parkinson’s by cell replacement therapy is relatively easy. Since loss of dopamine in Parkinson’s Disease brains causes its symptoms, all that is needed to treat the disease is replacement of the dopamine source. To have a beneficial effect, it only matters that transplanted cells are able to grow and release dopamine.

Unfortunately, this is not the case in Huntington’s disease. Medium spiny neurons in the striatum have many intricate connections with other neurons in the brain. The medium spiny neurons are required to both receive information from these other regions, as well as pass the information along.

Not surprisingly, this process can get pretty complicated, as the formation of connections between neurons starts when we’re developing in the womb and continues throughout our lives. These connections form and reform based on genetics and experience.

So, we might not expect that replacing medium spiny neurons would repair the devastating effects of Huntington’s disease, because it’s unlikely that replacement cells would be able to re-form the specific connections with other cells in the brain.

Proof of concept in a mouse brain

Interested in testing this this cell replacement idea, a team at the University of Wisconsin lead by Su-Chun Zhang recently injected replacement cells into mice whose striatum had been damaged. They found that the transplanted cells are capable of forming new connections in an adult mouse brain, and even more importantly, that these connections can improve the movement abnormalities of the mouse model.

The cells transplanted into the brains of mice were generated from human embryonic stem cells. Human embryonic stem cells are obtained from early stage embryos discarded after in vitro fertilization (IVF) procedures. These cells can develop into every cell type in the human body, including neurons and other brain cells.

The advantage using embryonic stem cells, as opposed to obtaining neurons from fetal tissues, is the ability of stem cells to continuously regenerate, creating a more consistent source of tissue.

Sonic hedgehog: the secret to spiny neurons?

What makes one cell type different from another is the collection of proteins that they produce, which allows the cells to take on different shapes and functions.

For example, a neuron, which transmits impulses that allow us to think and move, has a very different role in the body from the cells that line our intestines and absorb nutrients. To make a neuron from a stem cell, the action of proteins called transcription factors make the stem cell gradually more specialized. Transcription factors work by turning on some genes, while turning other genes off.

Zhang’s team treated the human embryonic stem cells with a transcription factor called ‘Sonic Hedgehog’ or a chemical that mimics its affects, and triggered the cells to transform into neurons. These man-made neurons looked like mature medium spiny neurons – the specific cells lost early on in Huntington’s disease.

Replacing neurons in the mouse brain

In the past, before the genetic basis for Huntington’s disease was understood, researchers would model the disease in mice by treating them with a neurotoxin called Quinolinic acid.

Quinolinic acid treatment doesn’t cause HD, but it causes medium spiny neurons in the striatum to die, which also happens in HD.

These days, mouse models are much more advanced – they carry CAG repeat mutations in the mouse huntingtin gene or an extra copy of a mutant huntingtin gene. These genetic mouse models experience physical and behavioural symptoms similar to the real disease.

In their recent work, Zhang’s group used Quinolinic acid to mimic the cell loss in Huntington’s Disease, and then replaced the lost cells by injecting the medium spiny neuron-like cells they generated from human embryonic stem cells.

They were happy to discover that not only did the newly formed neurons grow in the brains of the mice, but they were also able form the correct connections with surrounding tissues. When the movement functions of the mice were tested, they showed moderate improvement in symptoms.

Hopes and limitations

This work is hopeful, as it suggests that transplanted neurons have more capacity to form functional connections than previously predicted. That means that cell-based therapy for Huntington’s disease could be a real possibility in the future.

However, it must be noted that this study uses a Quinolinic acid treated mouse model, where the other, unaffected neurons are healthy. That’s not the case in a real HD-affected brain. The formation of healthy connections may be more difficult in HD patients.

Furthermore, the mice used in this study received radiation treatment to disable the immune system, meaning that they will not reject the transplanted tissues. Although the brain is usually protected from our immune systems, there is still a be risk of rejection of the transplanted tissue after surgery. So if this were tried in human patients, they’d likely need to take drugs to suppress the immune system, putting them at risk of developing serious infections.

With cell-based therapy, especially using tissues generated from embryonic stem cells, there is also a risk of uncontrolled cell growth – which could result in cancer. There are real questions about how we stop the transplanted cells from growing when they’re done replacing the dead cells.

Clearly, cell replacement treatments will need to be further refined before any clinical trials can take place. But this new piece of work suggests that new neurons might be more flexible than we previously thought.

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Updates from the EHDN Plenary Meeting 2020

Published date: 8 January, 2021

In September, the European Huntington’s Disease Network (EHDN) hosted a virtual webinar event which comprised presentations on some of the latest scientific research as well as clinical studies of Huntington’s disease (HD). Researchers, doctors, patients and other interested folks, tuned in for an afternoon of talks as well as question and answer sessions to learn ... Read more

Uncovering the dark side of DNA repair to design HD treatments

Published date: 22 December, 2020

A gene known as ‘MSH3’, which encodes a protein involved in fixing and maintaining our DNA, has become a hot topic in Huntington’s research since being implicated as a key driver of the disease by multiple genetic studies. In a recent publication, a team of scientists from the National University of Ireland, Galway, have provided ... Read more

Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus – Day 2

Published date: 1 November, 2020

The second day of the HSG conference was another busy day of presentations from HD researchers and clinicians. The day kicked off with a talk from Vaccinex who gave us an overview of their work on the SIGNAL clinical trial. Unfortunately, pepinemab, the medicine tested in this trial, did not influence HD symptoms and the ... Read more

Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus – Day 1

Published date: 30 October, 2020

The Huntington Study Group (HSG) is a clinical research network focused exclusively on HD. Yesterday the HSG annual conference began with a schedule jam-packed with virtual talks from researchers, clinicians and different companies who are all working towards finding new medicines for HD. The day encompassed many interesting presentations which covered a lot of the ... Read more

Treatment for neurological disorder could be repurposed for Huntington’s disease patients

Published date: 22 October, 2020

While developing a drug called branaplam for patients with SMA, the pharmaceutical company Novartis discovered that it could hold promise for people with HD. The FDA has granted a special status called Orphan Drug Designation to branaplam. An existing drug…for huntingtin lowering? The pharmaceutical company Novartis has announced that the U.S. Food and Drug Administration ... Read more

Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

Published date: 23 September, 2020

The SIGNAL clinical trial was designed to test a drug called pepinemab in people with early Huntington’s disease. The key results of that trial were recently announced, and unfortunately, pepinemab did not slow or improve HD symptoms as hoped. What was the SIGNAL trial, and who participated? The SIGNAL trial was launched in 2015 by ... Read more